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Karilysin is the only metallopeptidase identified as a virulence factor in the
odontopathogen Tannerella forsythia owing to its deleterious effect on the host
immune response during bacterial infection. The very close structural and
sequence-based similarity of its catalytic domain (Kly18) to matrix metallo-
proteinases suggests that karilysin was acquired by horizontal gene transfer
from an animal host. Previous studies by phage display identified peptides with
the consensus sequence XWFPXXXGGG (single-letter amino-acid codes; X
represents any residue) as karilysin inhibitors with low-micromolar binding
affinities. Subsequent refinement revealed that inhibition comparable to that of
longer peptides could be achieved using the tetrapeptide SWFP. To analyze its
binding, the high-resolution crystal structure of the complex between Kly18 and
SWFP was determined and it was found that the peptide binds to the primed
side of the active-site cleft in a substrate-like manner. The catalytic zinc ion is
clamped by the -amino group and the carbonyl O atom of the serine, thus
distantly mimicking the general manner of binding of hydroxamate inhibitors to
metallopeptidases and contributing, together with three zinc-binding histidines
from the protein scaffold, to an octahedral-minus-one metal-coordination
sphere. The tryptophan side chain penetrates the deep partially water-filled
specificity pocket of Kly18. Together with previous serendipitous product
complexes of Kly18, the present results provide the structural determinants of
inhibition of karilysin and open the field for the design of novel inhibitory
strategies aimed at the treatment of human periodontal disease based on a
peptidic hit molecule.
1. Introduction
Bacterial infection is responsible for periodontitis, an inflammatory
gum disease that affects 10–15% of adults worldwide (Petersen &
Ogawa, 2005). In the most severe forms of the disease, which may
result in tooth loss, three bacterial species are found which form the
‘red complex’: Porphyromonas gingivalis, Treponema denticola and
Tannerella forsythia (Socransky et al., 1998; Roˆc¸as et al., 2001).
Infection entails the secretion of virulence factors that contribute to
disease progression, and among such factors are proteolytic enzymes.
In T. forsythia, proteolytic virulence factors have been found to
include the cysteine proteinase PrtH, the trypsin-like serine
proteinase BspA and, most recently, the metallopeptidase (MP)
karilysin, which is responsible for the degradation of bactericidal
peptides and the inactivation of host complement (Sharma, 2010;
Karim et al., 2010; Cerda`-Costa et al., 2011; Koziel et al., 2010; Jusko et
al., 2012). Karilysin and Bacillus anthracisMmpZ (Pomerantsev et al.,
2011) are the only members of the matrix metalloproteinase (MMP)
family within the metzincin clan of MPs (Gomis-Ru¨th, 2003, 2009)
characterized from bacteria, which strongly suggests that these
proteins arose from eukaryotic-to-prokaryotic horizontal gene
transfer, resulting in xenology (Cerda`-Costa et al., 2011). Recently,
the three-dimensional structure of the catalytic MMP-like domain of
karilysin, Kly18, was analyzed with and without magnesium (Cerda`-
Costa et al., 2011), as alkaline-earth metals had been reported to be
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Figure 1
The complex between Kly18 and the SWFP tetrapeptide.
(a) Ribbon-type plot in cross-eyed stereo of Kly18 in
the standard MP orientation (Gomis-Ru¨th et al., 2012)
showing the regular secondary-structure elements
(-helices as ribbons labelled A–C and -strands as
arrows labelled I–V). The segment delimiting the S1
0
pocket is shown with its constituent parts in blue (Met-
turn), orange (S1
0 wall-forming segment) and yellow
(specificity loop). Residues participating in the binding
of the two zinc ions (magenta spheres) are shown with
their side chains as tan C atoms and are labelled. The
tetrapeptide is shown as a stick model with pink C atoms.
The tentative potassium cation is displayed as a purple
sphere. (b) Initial OMIT (2Fobs  Fcalc)-type electron
density in cross-eyed stereo contoured at 0.8 above the
threshold and centred on the final refined model of the
inhibitory tetrapeptide (Ser1-Trp2-Phe3-Pro4). (c) Close-
up view of (a) in cross-eyed stereo centred on the active-
site cleft. Protein residues participating in delimiting the
specificity pocket are shown as sticks with tan C atoms and
are labelled if not labelled in (a). Solvent molecules are
shown as cyan spheres. The side chain of Leu115 is in a
double conformation. (d) Superposition in cross-eyed
stereo of Kly18 in the present complex (protein in tan,
inhibitor in pink) and in the serendipitous product
complexes of its previously described magnesium-depleted
(PDB entry 2xs3; protein in pale green, peptide in dark
green) and magnesium-bound (PDB entry 2xs4; protein in
pale blue, peptide in dark blue) forms (Cerda`-Costa et al.,
2011). The view is similar to that in (c). The cations
correspond to those of the SWFP complex.
required for activity (Karim et al., 2010). In
addition, initial inhibitory studies of karilysin
identified several phage display-selected
peptides with apparent inhibition constants (Ki)
in the micromolar range, among which was the
tetrapeptide SWFP (Ki = 10.7 mM; Skottrup et
al., 2012).
In order to understand the structural deter-
minants of this inhibition, which would allow us
to identify hit compounds for the development of
drugs against Kly18, we determined the high-
resolution X-ray crystal structure of the Kly18–
SWFP complex. The results pave the way for the
design of novel therapeutic strategies to palliate
the effects of periodontal disease.
2. Materials and methods
2.1. Crystallization
Kly18 was prepared as reported by Karim et
al. (2010). The complex between Kly18 and the
SWFP peptide (Skottrup et al., 2012) was
obtained by mixing them in a 1:2 (enzyme:inhi-
bitor) molar ratio (protein at 8.0 mg ml1 and
peptide at 5.3 mg ml1, both in buffer consisting
of 5 mM Tris–HCl, 5 mM calcium chloride) and
incubating the mixture at room temperature for
1 h. Crystallization assays were performed by the
sitting-drop vapour-diffusion method. Reservoir
solutions were prepared using a Tecan robot and
100 nl crystallization drops were dispensed onto
96  2-well MRC plates (Innovadyne) by a
Phoenix nanodrop robot (Art Robbins) at the
High-Throughput Crystallography Platform (PAC) at Barcelona
Science Park. Plates were stored in Bruker steady-temperature
crystal farms at 277 and 293 K. Successful conditions were scaled up
to the microlitre range in 24-well Cryschem crystallization dishes
(Hampton Research). The best crystals were obtained at 293 K from
1:1 ml drops of complex solution (8 mg ml1 in 5 mM Tris–HCl pH 8,
5 mM calcium chloride, 0.02% sodium azide) with 0.4M sodium/
potassium tartrate as the reservoir solution. Crystals were cryopro-
tected by immersion into cryosolution [0.32M sodium/potassium
tartrate, 25%(v/v) glycerol].
2.2. Diffraction data collection
A complete diffraction data set was collected at 100 K from a
liquid-nitrogen flash-cryocooled crystal (Oxford Cryosystems 700
Series Cryostream) using an ADSC Q315R CCD detector on
beamline ID14-4 of the European Synchrotron Radiation Facility
(ESRF, Grenoble, France) within the Block Allocation Group
‘BAG Barcelona’. This crystal was body-centred tetragonal, with one
complex per asymmetric unit, and was isomorphous to the previously
reported magnesium-liganded form of Kly18 (Cerda`-Costa et al.,
2011). Diffraction data to 1.55 A˚ resolution were integrated, scaled,
merged and reduced with the programs XDS and XSCALE (Kabsch,
2010; see Table 1).
2.3. Structure determination
The structure of the Kly18–SWFP complex (Fig. 1a) was solved by
Fourier synthesis using the coordinates of the protein part only of the
magnesium-liganded structure (PDB entry 2xs4; Cerda`-Costa et al.,
2011). Initial crystallographic refinement with the program BUSTER/
TNT (Blanc et al., 2004), which included TLS refinement, yielded
an electron-density map that readily revealed that the inhibitor was
anchored to the active-site cleft of the enzyme (Fig. 1b). Subsequent
cycles of model building with Coot (Emsley et al., 2010) were alter-
nated with crystallographic refinement with BUSTER/TNT until
completion of the model. The final model contained residues Tyr35–
Asn53 and Leu58–Phe200 (protein residue numbering from UniProt
sequence database entry D0EM77), four cations (two zinc, one
potassium and one sodium, which replaces a solvent molecule found
in the previous magnesium-bound structure), four glycerol molecules
and 208 solvent molecules (see Table 2). Only the loop connecting
strand I to helix A (LIA; for the nomenclature and the extent
of the regular secondary-structure elements, see Figs. 1a and 2c in
Cerda`-Costa et al., 2011) was partially disordered and was not traced
for Ser54–His57.
2.4. Miscellaneous
Figures were prepared with CHIMERA (Pettersen et al., 2004).
Model validation was performed with MolProbity (Chen et al., 2010)
and the WHATCHECK routine of WHAT IF (Vriend, 1990). The
final coordinates of the complex between T. forsythia Kly18 and
the SWFP tetrapeptide have been deposited in the PDB (http://
www.pdb.org) as entry 4in9. The apparent inhibition constant (Ki) of
the peptide AFTS against Kly18 was determined as described by
Skottrup et al. (2012).
3. Results and discussion
3.1. Structure of Kly18
The successful crystallization of Kly18–SWFP complex previously
formed in solution only occurred under conditions containing
sodium/potassium tartrate; these conditions were thus unrelated to
those employed to obtain the magnesium-unbound and magnesium-
bound forms (Cerda`-Costa et al., 2011). The latter crystallized using
45% 2-methyl-2,4-pentanediol, 0.2M ammonium acetate, 0.1M Tris–
HCl pH 8.5 and 14% sodium polyacrylate 5100, 20 mM magnesium
chloride, 0.1M HEPES pH 7.5, respectively, as reservoir solutions.
The present crystals, however, were isomorphous to the magnesium-
bound form and belonged to the tetragonal space group I4 (compare
Table 1 with Table 2 of Cerda`-Costa et al., 2011).
The structure of Kly18 conforms to the overall fold of MMPs
(Tallant et al., 2010) as described previously (Cerda`-Costa et al.,
2011). Briefly, it has a compact globular shape (Fig. 1a) traversed by a
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Table 2
Structure-refinement and validation statistics.
Resolution range used for refinement (A˚) 1–1.55
No. of reflections in working set/test set 24983/1335
Crystallographic R factor/free R factor† 0.145/0.171
No. of protein atoms‡ 1311
No. of peptide atoms 39
No. of solvent molecules 208
No. of ligands 4 (CH2OH)2CHOH
No. of ions 2 Zn2+, 1 K+, 1 Na+
R.m.s.d. from target values
Bond lengths (A˚) 0.010
Bond angles () 0.92
Overall average B factor (A˚2) 17.6
Model validation§
Main-chain conformational angle analysis
Residues in favoured regions 156 (97.5%)
Outliers 0
All residues 160
Poor rotamers (%) 0.72
Residues with bad bonds 0
Residues with bad angles 0
C deviations > 0.25 A˚ 0








hkl jFobsj, where k is a scaling
factor and Fobs and Fcalc are the observed and calculated structure-factor amplitudes,
respectively. This factor is calculated for the working-set reflections; the free R factor
is calculated in the same way for a test set of reflections (>500) not used during
refinement. ‡ Including atoms with double occupancy. § According to MolProbity
(Chen et al., 2010).
Table 1
Data-collection and processing statistics.




Data-collection date 31 July 2012
No. of frames 180
Exposure time (s) 1
Rotation increment () 1
Refined crystal-to-detector distance (mm) 239.4
Crystal mosaicity () 0.424
Space group I4
Unit-cell parameters (A˚) a = 86.05, c = 49.44
Wavelength (A˚) 0.9393
No. of measurements/unique reflections 183548/26344
Resolution range (A˚) 42.9–1.55 (1.59–1.55)
Completeness (%) 99.9 (98.7)
Rmerge† 0.081 (0.749)
Rr.i.m. (= Rmeas)† 0.088 (0.854)
hI/(I)i 18.4 (2.1)
Wilson B factor (A˚2) 21.2









i IiðhklÞ; Rr.i.m. =
P
hklfNðhklÞ=




i IiðhklÞ, where Ii(hkl) is the ith intensity
measurement and nhkl is the redundancy of reflection hkl, including symmetry-related
reflections, and hI(hkl)i is its average intensity. Rr.i.m., the redundancy-independent
merging R factor (also known as Rmeas), is an improved multiplicity-weighted indicator of
the quality of the data. For details, see Weiss (2001) and Evans (2006).
shallow active-site cleft with a catalytic zinc ion at its bottom at half
cleft-width. The former separates an upper N-terminal subdomain
(NTS) from a lower C-terminal subdomain (CTS). The NTS consists
of a twisted five-stranded -sheet (strands I–V), two -helices
(the ‘backing helix’ A and the ‘active-site helix’ B) and an ‘S-loop’
(LIIIIV), which encompasses the binding site for a second struc-
tural zinc ion. The CTS contains the ‘Met-turn’, centred on Met173,
which creates a hydrophobic pillow for the catalytic metal-binding
site and is essential for the integrity of the site in MMPs and other
members of the metzincin clan of MPs (Tallant et al., 2010). In
addition, the ‘C-terminal helix’ C and a second structural cation-
binding site, which is most likely to contain a potassium ion owing to
geometric considerations (Harding, 2002) and its abundance in the
crystallization conditions, are found in the CTS. The possible potas-
sium is liganded in a distorted hexagonal coordination by six O atoms
(2.7–3.0 A˚ apart) provided by the main-chain carbonyls of Ser75,
Ser78 and Leu80 and by three solvent molecules.
As in MMPs in general, the catalytic zinc ion is bound by three
histidines (here His155, His159 and His165) contained in a long
consensus sequence characteristic to metzincins, HEXXHXXGXXH,
which also contains the general base/acid glutamate, Glu156, required
for catalysis (Tallant et al., 2010). The top of the active-site cleft is
shaped on its nonprimed side (for cleft-site nomenclature, see Gomis-
Ru¨th et al., 2012; Schechter & Berger, 1967) by the ‘upper-rim strand’
IV of the NTS -sheet and on its primed side by the final stretch
of the S-loop, termed the ‘bulge-edge segment’. The bottom of the
active-site cleft on its primed side is in turn delimited by the segment
bridging the Met turn and helix C, which includes the ‘S1
0 wall-
forming segment’ (Pro175–Tyr177) at the front and the ‘specificity
loop’ (Gly179–Gln183) at the back (Fig. 1a). Together with the first
turn of the active-site helix B, the latter three structural elements
contribute to shaping the size and the chemical nature of the S1
0 (or
specificity) pocket in Kly18 and also in MMPs in general (Tallant et
al., 2010).
3.2. Inhibitor binding
The structure revealed the unambiguous presence of the tetra-
peptide (Ser1-Trp2-Phe3-Pro4; peptide residues are shown in italics)
in the initial (OMIT) electron-density maps (Fig. 1b). It is firmly
anchored in a substrate-like manner to the primed side of the cleft,
with the N-terminal -amino group of Ser1 bound to the catalytic zinc
(at a distance of 2.2 A˚), the O"2 atom of Glu156 (2.9 A˚) and a solvent
molecule (2.9 A˚). The latter is itself further anchored to Glu156 O"1
(3.0 A˚) and a second solvent molecule (2.7 A˚; Fig. 1c). These two
solvent molecules possibly mimic authentic substrate-atom positions
on the nonprimed side of the cleft in Michaelis complexes. The
overall arrangement of the inhibitor N-terminus strongly suggests
that Ser1 N is in its uncharged NH2 protonation state, while Glu156 is
possibly present as an anionic carboxylate. In contrast to true peptidic
substrates in Michaelis complexes, none of the peptide main-chain
atoms contact the protein main chain directly, with the only exception
being Phe3 N, which forms a hydrogen bond to Pro175 O of the S1
0
wall-forming segment (at a distance of 2.8 A˚).
Considering the peptide side chains, Ser1 points away from the
protein moiety into bulk solvent and is in van der Waals contact with
the zinc-binding His165 (Ser1 O  His165 C"1, 3.1 A˚). The bulky
aromatic side chain of Trp2 penetrates the S1
0 pocket of the enzyme,
which is lined by the side chains of Leu73, Ile114–Leu115, Val152,
His155, His165, Leu172–Tyr177 and Lys181–Arg182 (Fig. 1c).
However, the presence of six solvent molecules at the bottom of the
pocket indicates that the indole side chain far from fills it completely.
In addition, Lys181 from the specificity loop closes the bottom of the
pocket and is kept in place by a double hydrogen bond to the main-
chain O atoms of the segment preceding the Met-turn (Lys181 N  
Ser169 O and Lys181 N  Ala171 O; both 2.9 A˚). The positive
charge of the lysine "-amino group is not compensated by any protein
residue. Downstream of Trp2, Phe3 again points away from the cleft,
but its side chain resides on a hydrophobic base which gives rise to
the cleft subsite S2
0 and is created by the side chains of the zinc-
binding His165 and the S1
0 wall residues Pro175 and Tyr177. After
Phe3, the inhibitor peptide chain leaves the molecular surface of
Kly18, so that Pro4, which is not so well defined by electron density
(Fig. 1b), projects into the bulk solvent.
3.3. Comparison with previous Kly18 structures
Overall, the structure of SWFP-inhibited Kly18 is very similar to
the previously reported structures of its magnesium-unbound (PDB
entry 2xs3) and magnesium-bound (PDB entry 2xs4) variants (Fig. 1d;
Cerda`-Costa et al., 2011). In these structures, which were determined
to resolutions of 2.40 and 1.70 A˚, respectively, we had serendipitously
trapped short peptides, which were probably C-terminal cleavage
products resulting from the purification procedure, of four and three
residues, respectively, on the primed side of the cleft, which were
tentatively interpreted as AFT(S). Interestingly, we could not detect
any inhibitory activity of the tetrapeptide AFTS towards Kly18 even
at 0.125 mM. Superposition of the three structures reveals that they
coincide overall except for the disorder found in LIA in the
present complex and in the bulge-edge segment spanning Asp109–
Ile114 (Fig. 1d). In the magnesium-unbound form this segment is
completely folded out towards downstream primed positions of the
cleft when compared with the other two structures, resulting in
a maximal displacement of 12 A˚ for Thr112 C between the
magnesium-unbound structure and the present complex structure.
This suggests that the bulge-edge segment is flexible and is capable of
adopting several conformations without affecting substrate, product
or inhibitor binding, at least with respect to short peptides covering
positions up to P3
0.
In addition, a magnesium ion is found in the magnesium-bound
form of Kly18 coordinated by an octahedral-minus-one ligand sphere,
with the apical position that points towards bulk solvent being
unoccupied, close to the position of the structural potassium of the
SWFP complex and with similar ligands (except for Leu80 O) but
much shorter binding distances (2.1–2.5 A˚). Overall, the polypeptide
chain traces (Ser75–Ser81) coincide not only in the two ion-bound
structures but also in the ion-depleted structures, suggesting that
there is no evident structural explanation for the requirement of
calcium for activity or ion binding in this region in general (Karim et
al., 2010; Cerda`-Costa et al., 2011).
The overall structural similarity of the Kly18 complexes extends to
the binding mode of the peptides to the active-site cleft (Fig. 1d),
in particular for their side chains, thus supporting the structural
conclusions derived from the present inhibitory-peptide complex
structure. In particular, the preference of Kly18 for bulky hydro-
phobic residues in the P1
0 position of substrates, as determined by
applying the CLiPS methodology (Karim et al., 2010), is met by Trp2
in the present structure and by a phenylalanine in the other two
structures.
4. Conclusion
We conclude that the inhibitory tetrapeptide SWFP binds to Kly18 in
a very similar manner to the products left behind in the primed side of
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the active-site cleft after cleavage of substrates. Both the presence of
solvent molecules in the specificity pocket below the indole side chain
of Trp2 and the unbalanced positive charge of the pocket-bottom
residue Lys181 strongly suggest that a chemically modified side chain
that is bulky and hydrophobic at the peptide-proximal end but that is
provided with a negatively charged group 8.6 A˚ from the position
of the Trp2 C atom could yield a much stronger and specific inhi-
bitor of Kly18 than SWFP. In addition, the lack of contact of Pro4
with the protein moiety suggests that substrate-subsite positions
beyond P3
0 are probably not relevant for the design of specific active-
site inhibitors of Kly18. Further experiments will be required to verify
these points and could pave the way to the design of small-molecule
inhibitors that may assist in the development of novel drugs to
combat Tannerella infection.
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